Fluciclovine F 18

(Axumin®)

Axumin®

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 9-221 mCi/mL)
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

Product Monograph / Prescribing Information

Document TitleYearSource
Axumin (fluciclovine F 18) Prescribing Information.2022Blue Earth Diagnostics Ltd., Oxford, UK

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.2022European Radiology
18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis.2022Radiology Imaging Cancer
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.2022European Journal of Nuclear Medicine and Molecular Imaging
18F-fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis.2021Diagnostics
The diagnostic role of 18 F-choline, 18 F-fluciclovine and 18 F-PSMA PET/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis.2021Frontiers in Oncology
18F-fluciclovine PET for assessment of prostate cancer with histopathology as reference standard: a systematic review.2021PET Clinics
Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review.2021European Urology Journal
18F-fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review.2021Prostate Cancer and Prostatic Diseases
Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. 2021European Journal of Nuclear Medicine and Molecular Imaging
PSMA-targeted radiotracers versus 18 F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis.2020Radiology
Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis.2020Frontiers in Oncology
Axumin for functional imaging of prostate cancer recurrence.2019NICE
18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis.2019Cancers
The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis.2019Clinical Radiology
UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging.2019Nuclear Medicine Communications
Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer.2018Translational Andrology and Urology

Clinical Practice Guidelines

Document TitleYearSource
[18F]fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0.2019European Journal of Nuclear Medicine and Molecular Imaging